Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting (Angiolipo)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01932021|
Recruitment Status : Unknown
Verified April 2014 by University Hospital, Caen.
Recruitment status was: Recruiting
First Posted : August 30, 2013
Last Update Posted : April 9, 2014
The hypertensive leg ulcer is a very painful leg related to acute skin microangiopathy. It occurs in patients older than 60 years followed for hypertension. Clinical diagnosis requires eliminating other causes arterial ulcers, cryoglobulinemia, thrombophilia, cholesterol crystal emboli, vasculitis associated with hepatitis C, myeloproliferative disorders and ulcers associated with the Hydrea ® outlet.
There is no treatment of the ulcer because conventional treatments are ineffective. The pain has subsided by analgesics III. Other treatments are not effective outside skin grafts to be repeated because they necrotic regularly. In a prospective uncontrolled study, 11 patients healed through autohemotherapy.
Ineffective treatment of this painful condition and efficiency of these cells to the damaged tissue, due to the secretion of many bioactive molecules, led us to propose subcutaneous injections of autologous fat to change the wound bed, promote healing and eliminate pain. This treatment should help to avoid long-term hospitalization (about 15 days) that can lead to physical and psychological degradation of these elderly patients.
The investigators propose an open clinical study of 10 patients with a single-center recruitment (CHU Caen). The study took place over a period of 18 months with a 12-month recruitment and follow-up of 6 months for each patient.
The purpose of this study was to evaluate the one hand, tolerance, in terms of pain and side effects, and, on the other hand, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound. The measure of effectiveness will also focus on the changing appearance of the wound, including the relative areas of fibrin, necrosis and budding. These efficiency measures (area ratio) will be done through a computer program (CANVAS ®) on photographs taken at each assessment time.
Eventually, if this study was to demonstrate the effectiveness of this treatment lipofilling, it would be possible to perform a multicenter study on a large number of patients to demonstrate the effectiveness, in terms of wound healing that the pain it causes and offer a shorter hospital stay, and in parallel, this approach should improve the pathophysiology of ulceration (translational research).
|Condition or disease||Intervention/treatment|
|Skin Ulcer||Procedure: adipose tissue grafting|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||April 2014|
|Estimated Study Completion Date :||December 2014|
|Experimental: adipose tissue grafting||Procedure: adipose tissue grafting|
- Treatment of hypertensive leg ulcer by adipose tissue grafting [ Time Frame: one year ]The objective of this study is to evaluate pain
- treatment of angiodermatitis necrotitis by lipofilling [ Time Frame: one year ]
Other objectives are to evaluate the tolerance, in terms of pain and side effects, and secondly, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound.
The objective also covers the measurement of changes in the appearance of the wound, with an expected decrease of relative areas of fibrin and necrosis. The percentage of wound healing and wound area was measured at each visit, a curve will be performed for each patient to assess the speed of healing and the appearance of the wound will be notified.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01932021
|Contact: Anne Dompmartin-Blanchère||+33 2 31 27 25 email@example.com|
|Contact: Marianne Chopinaud||+33 6 85 82 29 firstname.lastname@example.org|
|University Hospital, Caen||Recruiting|
|Caen, France, 14 000|
|Contact: Anne Dompmartin +33 2 31 27 25 09 email@example.com|
|Contact: Marianne Chopinaud +33 6 85 82 29 42 firstname.lastname@example.org|
|Principal Investigator: Anne Dompmartin, MD|
|Principal Investigator:||Anne Dompmartin, MD||University Hospital, Caen|